Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is a very rare genetic condition that affects growth and development before birth. It is usually recognized on prenatal scans or at birth, and common features include severe growth restriction, brain abnormalities, a small head, tight joints, and distinctive skin and facial changes. Not everyone will have the same experience. This condition is lifelong, but the most severe forms often lead to stillbirth or death soon after birth. There is no cure, so treatment focuses on supportive care, and specialist teams may also consider serine replacement in selected cases.
How many people live with Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
No reliable worldwide or U.S. count has been published for Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency. Rare-disease sources describe it as exceptionally rare, with only a handful of families reported worldwide and no separate U.S. estimate available (Orphanet, 2025; GeneReviews, 2023).
Overview
Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiencySymptoms
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency causes severe birth defects, often recognized before birth or at delivery. Common features include very poor growth, brain and skin changes, joint contractures, swelling, and serious problems with breathing and feeding.
Outlook and prognosis
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually a very severe condition, and many affected babies die before birth or shortly after delivery. In the rare milder cases, outlook depends on breathing, feeding, seizures, and overall brain development.
Causes and risk factors
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is caused by harmful changes in the PSPH gene. It is inherited when both parents pass on a nonworking copy. Family history and related parents can raise the chance.
Genetic influences
Genetics are central to Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency. It is caused by harmful changes in the PSPH gene, and the condition usually develops when a child inherits one changed copy from each parent.
Diagnosis
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually suspected from clinical features seen before or at birth. The diagnosis of Neu-Laxova syndrome is confirmed with genetic tests. Ultrasound imaging findings during pregnancy can also support diagnosis.
Treatment and drugs
Treatment for Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency often centers on L-serine, sometimes with glycine. Many living with this condition also need supportive care for feeding, breathing, seizures, and growth. Early specialist care can help guide treatment and comfort.
Symptoms
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency causes major problems with growth and body development before birth. Babies are often much smaller than expected and may have visible differences in the head, skin, face, and limbs. The early features of Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency are often seen on prenatal ultrasound or are clear at birth. Many babies also have serious brain and breathing problems, so this condition is usually very severe.
Babies with Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency are usually much smaller than expected during pregnancy and at birth. This severe poor growth can affect overall strength and resilience right from delivery.
During pregnancy, the baby may move less than expected. This can be an early clue that the muscles, joints, or nervous system are not developing normally.
The head is usually much smaller than expected for the stage of pregnancy or at birth. This often reflects poor brain growth and is a key feature of Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency.
Brain scans may show major differences in how the brain formed. For babies who survive birth, these changes can lead to severe developmental impairment, poor muscle control, or seizures.
How people usually first notice Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually first noticed during pregnancy, when ultrasound may show very poor growth, too little movement, extra fluid under the skin, or differences in how the brain, limbs, or face are developing. In many cases, the first signs of Neu-Laxova syndrome are also obvious at birth, with severe growth restriction, tight or shiny skin, joint contractures, and distinctive facial features that signal a serious genetic condition from the start. Because this syndrome is typically present before birth and causes major developmental problems, doctors and families usually recognize it very early rather than later in childhood.
Types of Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency
No distinct types of Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency are widely recognized.
Can I slow down the onset of symptoms?
No, there is no good evidence that lifestyle changes or standard medical care can meaningfully delay the start of symptoms in Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency, because it begins very early in pregnancy as part of a severe inherited condition. A few small reports have looked at closely supervised serine treatment during pregnancy in related rare disorders, but for this specific syndrome the evidence is too limited to say it can delay or prevent symptoms. If this condition runs in your family, early genetic counseling and care with a high-risk pregnancy team can help with testing and planning, which can be helpful even though it cannot promise a different outcome.
What genetics can tell you about symptoms
In Neu-Laxova syndrome caused by changes in the PSPH gene, genetics can confirm the cause and explain why symptoms are usually severe and begin before birth or at delivery. Because this condition is very rare, there is not enough evidence to predict a precise symptom pattern from a specific genetic change, but different changes in the gene may influence how severe the brain, growth, skin, and muscle-related problems are. In most families, the genetic result helps more with confirming the diagnosis and recurrence risk than with forecasting exactly which symptoms will appear in an individual baby.
Causes and risk factors
Most cases of Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency happen because of harmful changes in the PSPH gene, which reduce the body’s ability to make enough serine. It usually develops only when a baby inherits one changed copy from each parent, so the main biological risk is having two carrier parents. A family history of the condition and parents who are related by blood can raise the chance in a pregnancy. Lifestyle, diet, and common environmental exposures are not known to be the main cause, though researchers are still studying whether they affect severity. Genetic testing can sometimes clarify your personal risk of having a child with Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency.
What are the most common causes or risk factors?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is caused by inheriting two altered copies of the same gene, called PSPH, one from each parent; this gene helps the body make serine, a substance needed for normal growth and brain development. The main risk factor is having two parents who each carry one altered copy of this gene, even if they are healthy themselves. The chance is also higher when the parents are closely related by blood, and there are no known lifestyle or environmental risk factors that cause this condition.
Environmental and biological risk factors
For Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency, the established risks are mainly body-based and inherited rather than caused by common pregnancy exposures. Awareness of both biological and environmental influences helps you feel prepared. At this time, no specific outside exposure has been proven to trigger this condition.
This syndrome usually happens when both parents carry the same rare change in the PSPH gene, even though they are typically healthy themselves. When that is true, each pregnancy has a higher chance of being affected.
A previous pregnancy affected by Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency, or close relatives with the condition, raises concern that the same rare change is present in the family. This can increase the chance in future pregnancies.
When parents are biologically related, such as cousins, they are more likely to carry the same rare gene change. That makes very rare recessive conditions like this one more likely.
No specific maternal illness, infection, medication, toxin, radiation exposure, or age effect has been clearly shown to cause Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency. For this condition, outside exposures are not known to be major risk drivers.
Genetic risk factors
For families facing Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency, the main cause is a change in a single gene called PSPH. The condition develops when a child inherits two nonworking copies of this gene, one from each parent. Carrying a genetic change doesn’t guarantee the condition will appear. This makes family history and carrier testing especially important when thinking about future pregnancies.
PSPH variants: Harmful changes in both copies of the PSPH gene are the direct genetic cause of this form of Neu-laxova syndrome. This gene helps the body make serine, a building block that is especially important during early brain and body development.
Autosomal recessive: Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency follows an autosomal recessive inheritance pattern. This means a child is affected only when both copies of PSPH are not working.
Carrier parents: Parents who each carry one altered PSPH copy usually do not have symptoms themselves. In each pregnancy together, there is a 1 in 4, or 25%, chance of having an affected child, a 1 in 2, or 50%, chance of having a child who is a carrier, and a 1 in 4, or 25%, chance of having a child with two working copies.
Family history: A previous affected child or pregnancy strongly suggests that both parents may be carriers of a PSPH change. For many families, this is one of the clearest clues when looking into the genetic causes of Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency.
Related parents: When parents are biologically related, such as cousins, they are more likely to carry the same rare PSPH variant. That can raise the chance of an autosomal recessive condition like this one.
Known family variant: If a specific PSPH variant has already been found in the family, close relatives may also be carriers. In some cases, genetic testing can give a clearer picture of your personal risk.
Lifestyle risk factors
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is present from birth, so lifestyle habits do not cause it. However, how lifestyle affects Neu-Laxova syndrome is still important because daily care can influence feeding tolerance, comfort, respiratory stability, skin integrity, and the risk of complications. Evidence is limited because the condition is extremely rare, so recommendations are usually individualized and supportive rather than preventive.
Poor oral intake and swallowing difficulty can quickly worsen malnutrition and low energy in affected infants and children. Careful feeding routines, texture changes, or tube-feeding plans may improve growth support and reduce aspiration risk.
Inadequate fluid intake can worsen dehydration, irritability, constipation, and general medical instability. Close attention to hydration, especially during illness or hot weather, may help lower the risk of rapid clinical decline.
Limited mobility and abnormal muscle tone can increase discomfort, pressure injury risk, and breathing difficulty if positioning is poor. Regular repositioning, supported seating, and guided stretching may help protect joints, skin, and chest expansion.
Lifestyle risk factors for Neu-Laxova syndrome do not include exercise as a cause, but complete inactivity can worsen stiffness and loss of function. Gentle therapist-guided movement may support comfort, circulation, and day-to-day mobility within the child's limits.
Risk prevention
Because Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency is a rare inherited condition that begins before birth, it usually cannot be prevented once an affected pregnancy has started. In practice, how to prevent Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency is mostly about lowering the chance of another affected pregnancy through genetic counseling and testing. Families who have had an affected pregnancy, or know they may carry the gene change, can talk with a specialist before trying to conceive. Different people need different prevention strategies—there’s no single formula.
Meeting with a genetics specialist before pregnancy can clarify the chance of having a baby with Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency. This visit usually includes a review of family history, past pregnancies, and which tests may be most helpful.
Testing both biological parents can show whether they carry a changed copy of the PSPH gene linked to this form of Neu-laxova syndrome. If both are carriers, each pregnancy has a known chance of being affected, which can guide planning.
If one parent is already known to be a carrier, testing the other parent can better define the risk before pregnancy. This can be especially useful when there has been a previous affected baby or a pregnancy loss with similar findings.
Some families choose in vitro fertilization with preimplantation genetic testing to look for embryos that do not have Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency. This does not treat the condition, but it may reduce the chance of starting an affected pregnancy.
Can you prevent Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency cannot usually be prevented, because it is caused by a rare inherited gene change that is present from the very start of pregnancy. If this condition has happened in your family, meeting with a genetics specialist before pregnancy may help you understand the chance of it happening again and talk through testing options, but it cannot guarantee prevention.
Transmission
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is not an infection, so it is not contagious and cannot be spread from one person to another by touch, air, sex, food, or blood. Instead, how Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is inherited usually involves both parents passing on a changed copy of the same gene.
This is called an autosomal recessive pattern, which means parents are often healthy carriers and may not know they carry the gene change. When both parents are carriers, each pregnancy has a 1 in 4, or 25%, chance of the baby having Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency.
When to test your genes
Because this is a rare inherited condition present from the start, genetic testing is most useful before or during pregnancy if there is a family history, a previous affected pregnancy, or known parental carrier status. Testing can clarify recurrence risk and guide options such as carrier testing, prenatal diagnosis, or preimplantation genetic testing.
Diagnosis
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually diagnosed when a baby has a pattern of very severe growth and development problems before birth or at delivery. Doctors often suspect it from recognizable physical features and findings on pregnancy scans, then confirm the diagnosis of Neu-Laxova syndrome with genetic testing. Some conditions have a genetic link, meaning they can run in families. Because this condition is very rare and can overlap with other serious disorders, diagnosis often involves both fetal medicine and genetics specialists.
Prenatal ultrasound may show poor growth, too little movement, extra fluid under the skin, brain abnormalities, or contractures where joints stay fixed. These imaging findings can raise concern for Neu-Laxova syndrome before birth and help guide further testing.
After birth, doctors look for a combination of severe growth restriction, tight or shiny skin, limb contractures, and distinctive head and facial features. This clinical pattern helps them consider Neu-Laxova syndrome and separate it from other rare genetic conditions.
The genetic diagnosis of Neu-Laxova syndrome is made by finding disease-causing changes in both copies of the PSPH gene. Testing may be done on the baby after birth or during pregnancy using samples such as chorionic villus sampling or amniocentesis.
A detailed family and health history can help, especially if there were prior pregnancies affected by similar severe findings or known related gene changes in the family. Because this condition is inherited in an autosomal recessive pattern, parents are usually healthy carriers.
How is Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency diagnosed?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is often first suspected during pregnancy, when ultrasound shows severe poor growth and unusual changes in the brain, face, skin, or the way the arms and legs are held. After birth, doctors diagnose it by examining these physical features and may use brain scans and blood tests to look for very low levels of serine, a natural substance the body needs to grow and develop. A genetic test can then confirm the diagnosis by finding a disease-causing change in the PSPH gene.
Stages of Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency
Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency does not have defined progression stages. That is because it is a rare condition that is usually present before birth or at birth, rather than one that follows a clear step-by-step pattern over time. Doctors usually start with a conversation about pregnancy findings, the baby’s health at birth, and features seen on physical examination, along with imaging or other tests if needed. The diagnosis is usually confirmed with genetic testing, and monitoring focuses on the baby’s immediate medical needs rather than tracking early symptoms of Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency through set stages.
Outlook and prognosis
The outlook for Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is generally very poor. Most affected pregnancies end in stillbirth or death in the newborn period because of severe brain, skin, growth, and other congenital abnormalities. In infants who are born alive, life-threatening feeding and breathing problems, profound developmental impairment, and complications related to multisystem disease are common. Survival beyond infancy appears to be rare, although the exact prognosis can vary with the severity of the disorder and the level of supportive care available. Because this condition is exceptionally rare, long-term outcome data are limited, but overall mortality is very high.
Long-term effects
Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually a very severe, life-limiting condition. Many affected pregnancies end before birth, and many babies who are born alive survive only a short time because of serious problems affecting the brain, growth, feeding, and breathing. When families ask about life expectancy in Neu-laxova syndrome, the answer depends largely on how severe these early problems are, and Long-term effects vary widely in the rare children who survive beyond infancy.
The most important long-term issue is survival, because the condition is often fatal before birth or in the newborn period. In babies who survive, the outlook is still serious and usually involves ongoing complex medical needs.
Severe poor growth often continues over time, including low birth weight and very limited weight gain afterward. Many living with Neu-laxova syndrome also have a small head size, which reflects severe effects on brain development.
Survivors usually have profound developmental delay and severe intellectual disability. Over time, this can mean little or no independent sitting, standing, walking, or spoken language.
Tight joints, fixed limb positions, and marked muscle stiffness can persist long term. For many, this can limit movement, make daily care harder, and increase the risk of discomfort and pressure injuries.
How is it to live with Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is an extremely severe genetic condition, and for many affected babies, life is very short because the disorder often causes major problems with growth, brain development, skin, breathing, and feeding before or soon after birth. In the rare situations where a child survives longer, daily life usually involves complex medical needs, close hands-on care, and support for profound developmental disability, with families often spending much of their time coordinating appointments, feeding support, comfort care, and hospital-based treatment. The effects reach far beyond the child, because parents and loved ones often carry an intense emotional load, make difficult medical decisions, and need strong practical and bereavement support as they navigate a condition that is devastating and unpredictable.
Treatment and drugs
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is usually treated with supportive care, because there is no proven cure and the condition is often severe from before birth or in the newborn period. Treatment often looks different for each person, but it may include help with breathing and feeding, comfort care, treatment of seizures if they occur, and careful monitoring by a team that may include newborn specialists, neurologists, and palliative care clinicians. In some related serine-making disorders, doctors may consider supplements such as L-serine, but for Neu-Laxova syndrome the benefit is not well established and any use would need specialist guidance. Because this condition is genetic and can recur in families, genetic counseling is also an important part of care when people want to understand future pregnancy options.
Can you cure Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
No, there is no cure for Neu-Laxova syndrome caused by this rare genetic problem. Because it is a very severe condition that starts before birth, treatment cannot reverse it and usually focuses on comfort, treating problems that can be managed, and supporting the family. In some related conditions, special supplements may help a little, but they have not been shown to cure this syndrome.
Non-drug treatment
Daily care for people living with Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency usually centers on comfort, feeding, movement, and development rather than one single therapy. Because this condition can affect the brain, muscles, growth, and how a child eats and breathes, care is often planned by a team that follows changing needs over time. Supportive therapies can make day-to-day life easier, help prevent complications, and give families practical ways to handle feeding, positioning, and communication. Not every approach works the same way, so care is individualized based on symptoms and overall health.
Gentle stretching, guided movement, and positioning can help with stiffness, tight joints, and comfort. For many living with Neu-Laxova syndrome, this may also support easier handling, safer transfers, and better posture during daily care.
Occupational therapy focuses on practical daily activities such as positioning, hand use, seating, and adaptive equipment. Some may find it helps with comfort and participation, even when development is very limited.
A speech or feeding therapist can assess sucking, swallowing, and the safest ways to take food and fluids. Structured programs, like swallow therapy and texture changes, can help lower the risk of choking or food going into the lungs.
Careful nutrition planning can help with poor growth, low intake, or long feeding times. This often includes calorie support, feeding schedules, and, when needed, tube feeding guidance as part of supportive care for Neu-Laxova syndrome.
Your genes may have an impact on how drugs work for you
For Neu-Laxova syndrome caused by this serine-related enzyme problem, there is no well-established evidence that the genetic change itself changes how common medicines work in a predictable way. In real life, care is usually focused on comfort and support, so doctors choose medicines based more on a baby's symptoms, breathing, feeding, seizures if they happen, and overall medical fragility than on a known gene-based drug response. Because this condition is very rare and often severe, medicine use is usually individualized, with careful dosing and close monitoring rather than a standard gene-guided plan.
Pharmacological treatments
For many families, the hardest part is that there is no proven standard drug treatment that can reverse Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency. In the rare situation where treatment is attempted, doctors may consider replacing the missing body chemical with L-serine, sometimes together with glycine, because this disorder affects the body’s ability to make serine. Some medicines may also be used to ease symptoms such as seizures, but care is often supportive and highly individualized. Not everyone responds to the same medication in the same way.
L-serine is the main disease-targeted treatment doctors may consider, especially in serine deficiency disorders that are diagnosed early. It aims to raise serine levels in the body, but in severe Neu-Laxova syndrome it has not been shown to reverse major problems that began before birth. Dosing may be increased or lowered gradually to balance possible benefit and tolerability.
Glycine may be added with L-serine in some cases, since both are closely linked in brain metabolism. This approach is based on experience from related serine deficiency disorders rather than strong evidence in Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency.
If seizures occur, antiseizure drugs such as levetiracetam, phenobarbital, or other standard seizure medicines may be used to control symptoms. These drugs do not treat the underlying cause, but they may help reduce seizure burden and improve comfort.
Some babies may receive medicines for pain, feeding intolerance, reflux, or breathing-related distress, depending on their needs. Drug treatments aren’t about fixing everything at once, but about easing day-to-day problems and supporting comfort.
Genetic influences
In this form of Neu-Laxova syndrome, the genetic cause is established: disease-causing changes in the PSPH gene lead to 3-phosphoserine phosphatase deficiency. This is an autosomal recessive condition, which means a baby is affected only if they inherit one nonworking copy of the gene from each parent. A carrier means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has a 25% chance of Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency, a 50% chance that the child will be a carrier, and a 25% chance that the child will inherit neither changed copy. The PSPH gene helps the body make serine, a building block that is especially important for growth and brain development, so loss of this gene function can lead to the severe features seen in this condition. Because the cause is specific and inherited, genetic counseling and family testing can help relatives understand recurrence risk and how Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency is inherited.
Is Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency genetic?
Genetics are central to Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency. It is caused by harmful changes in the PSPH gene, and the condition usually develops when a child inherits one changed copy from each parent.
Having a genetic risk is not necessarily a diagnosis
Changes in genes are a normal part of human biology and are widespread in the general population. Most of these changes do not directly affect health and are simply part of natural human diversity. For many genes, having a change connected with a condition points to a possible link, not a certain diagnosis, especially when several genes and environmental factors play a role. In some situations, though, one well-understood change in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
In Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency, the gene change affects the body’s ability to make serine, a substance that is especially important for brain and body development. Because of that, treatment is guided by the genetic cause itself, not just by symptoms, and doctors may discuss whether L-serine supplements, sometimes along with glycine, could help in milder serine-related disorders or when treatment can begin very early. For many living with Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency, this means the main value of genetic testing is to confirm the exact diagnosis and guide realistic treatment choices, rather than to match someone to a long list of medicines. Still, this condition is often very severe, and supplements may not undo changes that happened before birth, so care may also focus on feeding, breathing, seizures, and comfort. Not every difference in response is genetic, but in this disorder the underlying gene change is the main reason standard medicines do not fix the root problem. Families can ask the care team whether the genetic result changes decisions about treatment for Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency, supportive care, and future pregnancy planning.
Interactions with other conditions
For families affected by Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency, the main concern is usually not whether it links with common chronic diseases, but how its severe effects can lead to other medical problems around pregnancy, birth, and the newborn period. Because this condition causes major problems with brain growth, skin, movement, and often the lungs, babies may also have trouble breathing, feeding, staying hydrated, or fighting infection, and those complications can quickly make the overall illness more serious. In practice, someone might notice their symptoms flare when another condition is active, but with Neu-laxova syndrome this is usually seen as added stress from infections or organ problems rather than a typical long-term disease overlap. Many living with this disorder do not survive pregnancy or the newborn period, so common later-life interactions with conditions such as diabetes or heart disease are not usually part of the picture. If a baby survives longer, doctors usually watch closely for seizures, poor growth, repeated infections, and breathing or feeding problems, since these can strongly affect daily care and comfort.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency?
Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency can look a lot like other very severe conditions that affect growth and brain development before birth, especially the other rare serine-related disorders and syndromes such as Pena-Shokeir syndrome and cerebro-oculo-facio-skeletal syndrome. In some pregnancies, severe chromosome conditions or serious infections before birth can also cause a similar pattern of very poor growth, a very small head, stiff joints, and multiple birth differences, so doctors usually use genetic testing and detailed scans to tell them apart.
History
For families facing Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency, the history can feel both distant and very personal. It often begins with doctors trying to make sense of a pattern of very severe problems seen before birth or at delivery, such as poor growth, changes in the brain and skin, and tight joints or limb differences. Early symptoms of Neu-Laxova syndrome were recognized long before the underlying biology was understood, so the first reports focused mainly on what doctors could see and describe.
In the 1970s, researchers began reporting babies with a striking combination of findings that later came to be grouped under the name Neu-Laxova syndrome. At first, it was considered a single, extremely rare condition defined by its physical features and serious effects on development. As medical science evolved, doctors learned that not every child with this diagnosis had exactly the same course or the same cause, even when the outward features looked similar.
That change mattered. Over time, laboratory testing and advances in genetics showed that some cases of Neu-Laxova syndrome are linked to problems in the body’s serine pathway, a process cells use to make an important building block needed for normal growth and brain development. This is where Neu-Laxova syndrome due to 3-phosphoserine phosphatase deficiency fits into the story: it is now understood as a specific cause within the broader Neu-Laxova picture, rather than just a pattern of symptoms.
This shift from description to explanation has helped doctors give families clearer answers, even though the condition remains very rare and very serious. It has also improved prenatal evaluation and allowed specialists to connect ultrasound findings, newborn features, and lab results in a more accurate way. Knowing this history helps explain why older medical reports may use broader language, while newer reports are more precise about the exact form of the condition.